The effect of pharmaceutical benefits managers: Is it being evaluated?

Kevin A. Schulman, L. Elizabeth Rubenstein, Darrell R. Abernethy, Damon M. Seils, Daniel P. Sulmasy

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Over the last decade, the number of pharmaceutical benefits managers has increased, and their influence has expanded rapidly. These managers now provide prescription drug coverage to more than 100 million Americans. The effect of pharmaceutical benefits managers on health care delivery remains unclear. We review the development of these organizations, their current role in the delivery of pharmaceutical therapies to patients, and their relationship with pharmaceutical manufacturers. We discuss potential advantages and disadvantages of pharmaceutical benefits manager practices and suggest ways in which these organizations can be made more accountable to the employer groups that hire them.

Original languageEnglish (US)
Pages (from-to)906-913
Number of pages8
JournalAnnals of internal medicine
Issue number10
StatePublished - May 15 1996
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'The effect of pharmaceutical benefits managers: Is it being evaluated?'. Together they form a unique fingerprint.

Cite this